Hasan Md Anayet, Khan Md Arif, Datta Amit, Mazumder Md Habibul Hasan, Hossain Mohammad Uzzal
Department of Genetic Engineering and Biotechnology, Faculty of Biological Sciences, University of Chittagong, Chittagong-4331, Bangladesh.
Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail-1902, Bangladesh.
Mol Immunol. 2015 May;65(1):189-204. doi: 10.1016/j.molimm.2014.12.013. Epub 2015 Feb 14.
Recent concerning facts of Chikungunya virus (CHIKV); a Togaviridae family alphavirus has proved this as a worldwide emerging threat which causes Chikungunya fever and devitalizing arthritis. Despite severe outbreaks and lack of antiviral drug, a mere progress has been made regarding to an epitope-based vaccine designed for CHIKV. In this study, we aimed to design an epitope-based vaccine that can trigger a significant immune response as well as to prognosticate inhibitor that can bind with potential drug target sites by using various immunoinformatics and docking simulation tools. Initially, whole proteome of CHIKV was retrieved from database and perused to identify the most immunogenic protein. Structural properties of the selected protein were analyzed. The capacity to induce both humoral and cell-mediated immunity by T cell and B cell were checked for the selected protein. The peptide region spanning 9 amino acids from 397 to 405 and the sequence YYYELYPTM were found as the most potential B cell and T cell epitopes respectively. This peptide could interact with as many as 19 HLAs and showed high population coverage ranging from 69.50% to 84.94%. By using in silico docking techniques the epitope was further assessed for binding against HLA molecules to verify the binding cleft interaction. In addition with this, the allergenicity of the epitopes was also evaluated. In the post therapeutic strategy, three dimensional structure was predicted along with validation and verification that resulted in molecular docking study to identify the potential drug binding sites and suitable therapeutic inhibitor against targeted protein. Finally, pharmacophore study was also performed in quest of seeing potent drug activity. However, this computational epitope-based peptide vaccine designing and target site prediction against CHIKV opens up a new horizon which may be the prospective way in Chikungunya virus research; the results require validation by in vitro and in vivo experiments.
基孔肯雅病毒(CHIKV)的近期相关事实;披膜病毒科甲病毒已被证明是一种全球范围内新出现的威胁,可导致基孔肯雅热和致残性关节炎。尽管爆发严重且缺乏抗病毒药物,但针对基孔肯雅病毒设计的基于表位的疫苗仅取得了些许进展。在本研究中,我们旨在设计一种基于表位的疫苗,该疫苗能够引发显著的免疫反应,并通过使用各种免疫信息学和对接模拟工具预测可与潜在药物靶点结合的抑制剂。最初,从数据库中检索基孔肯雅病毒的全蛋白质组,并仔细研究以确定最具免疫原性的蛋白质。分析所选蛋白质的结构特性。检查所选蛋白质诱导T细胞和B细胞产生体液免疫和细胞介导免疫的能力。发现分别跨越397至405位9个氨基酸的肽段和序列YYYELYPTM是最具潜力的B细胞和T细胞表位。该肽可与多达19种HLA相互作用,并显示出69.50%至84.94%的高人群覆盖率。通过使用计算机对接技术,进一步评估该表位与HLA分子的结合,以验证结合裂隙相互作用。除此之外,还评估了表位的致敏性。在治疗后策略中,预测三维结构并进行验证和核实,从而进行分子对接研究,以确定潜在的药物结合位点和针对靶向蛋白的合适治疗抑制剂。最后,还进行了药效团研究以寻找有效的药物活性。然而,这种基于计算机表位的肽疫苗设计以及针对基孔肯雅病毒的靶点预测开辟了一个新的领域,这可能是基孔肯雅病毒研究的前瞻性方法;结果需要通过体外和体内实验进行验证。